U.S. flag

An official website of the United States government

NM_000038.6(APC):c.7757G>T (p.Ser2586Ile) AND Hereditary cancer-predisposing syndrome

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Aug 31, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000570424.12

Allele description [Variation Report for NM_000038.6(APC):c.7757G>T (p.Ser2586Ile)]

NM_000038.6(APC):c.7757G>T (p.Ser2586Ile)

Gene:
APC:APC regulator of WNT signaling pathway [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
5q22.2
Genomic location:
Preferred name:
NM_000038.6(APC):c.7757G>T (p.Ser2586Ile)
HGVS:
  • NC_000005.10:g.112843351G>T
  • NG_008481.4:g.155831G>T
  • NM_000038.6:c.7757G>TMANE SELECT
  • NM_001127510.3:c.7757G>T
  • NM_001127511.3:c.7703G>T
  • NM_001354895.2:c.7757G>T
  • NM_001354896.2:c.7811G>T
  • NM_001354897.2:c.7787G>T
  • NM_001354898.2:c.7682G>T
  • NM_001354899.2:c.7673G>T
  • NM_001354900.2:c.7634G>T
  • NM_001354901.2:c.7580G>T
  • NM_001354902.2:c.7484G>T
  • NM_001354903.2:c.7454G>T
  • NM_001354904.2:c.7379G>T
  • NM_001354905.2:c.7277G>T
  • NM_001354906.2:c.6908G>T
  • NP_000029.2:p.Ser2586Ile
  • NP_001120982.1:p.Ser2586Ile
  • NP_001120983.2:p.Ser2568Ile
  • NP_001341824.1:p.Ser2586Ile
  • NP_001341825.1:p.Ser2604Ile
  • NP_001341826.1:p.Ser2596Ile
  • NP_001341827.1:p.Ser2561Ile
  • NP_001341828.1:p.Ser2558Ile
  • NP_001341829.1:p.Ser2545Ile
  • NP_001341830.1:p.Ser2527Ile
  • NP_001341831.1:p.Ser2495Ile
  • NP_001341832.1:p.Ser2485Ile
  • NP_001341833.1:p.Ser2460Ile
  • NP_001341834.1:p.Ser2426Ile
  • NP_001341835.1:p.Ser2303Ile
  • LRG_130:g.155831G>T
  • NC_000005.9:g.112179048G>T
  • NM_000038.5:c.7757G>T
Protein change:
S2303I
Links:
dbSNP: rs199806334
NCBI 1000 Genomes Browser:
rs199806334
Molecular consequence:
  • NM_000038.6:c.7757G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001127510.3:c.7757G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001127511.3:c.7703G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354895.2:c.7757G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354896.2:c.7811G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354897.2:c.7787G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354898.2:c.7682G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354899.2:c.7673G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354900.2:c.7634G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354901.2:c.7580G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354902.2:c.7484G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354903.2:c.7454G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354904.2:c.7379G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354905.2:c.7277G>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001354906.2:c.6908G>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV000667483Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)		Uncertain significance
(Aug 31, 2022) 		germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Citation Link

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes.

Johnston JJ, Rubinstein WS, Facio FM, Ng D, Singh LN, Teer JK, Mullikin JC, Biesecker LG.

Am J Hum Genet. 2012 Jul 13;91(1):97-108. doi: 10.1016/j.ajhg.2012.05.021. Epub 2012 Jun 14.

PubMed [citation]
PMID:
22703879
PMCID:
PMC3397257

Details of each submission

From Ambry Genetics, SCV000667483.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

The p.S2586I variant (also known as c.7757G>T), located in coding exon 15 of the APC gene, results from a G to T substitution at nucleotide position 7757. The serine at codon 2586 is replaced by isoleucine, an amino acid with dissimilar properties. This variant was also detected as a secondary finding in 1 out of 561 ClinSeq participants unselected for personal or family history of cancer who underwent exome sequencing, however the clinical information for this particular individual was not provided (Johnston JJ et al. Am. J. Hum. Genet., 2012 Jul;91:97-108). This amino acid position is highly conserved in available vertebrate species. In addition, in silico predictors for this gene do not accurately predict pathogenicity. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 1, 2024